2024

Frankell, A. M. et al. (2024) Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 631(8022), E15. (doi: 10.1038/s41586-024-07738-w) (PMID:38965439)

Quiros, A. C. et al. (2024) Mapping the landscape of histomorphological cancer phenotypes using self-supervised learning on unannotated pathology slides. Nature Communications, 15, 4596. (doi: 10.1038/s41467-024-48666-7) (PMID:38862472)

2023

Farahmand, P. et al. (2023) Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma. Frontiers in Toxicology, 5, 1200650. (doi: 10.3389/ftox.2023.1200650) (PMID:37441092) (PMCID:PMC10333928)

Hatthakarnkul, P. et al. (2023) Protein expression of S100A2 reveals it association with patient prognosis and immune infiltration profile in colorectal cancer. Journal of Cancer, 14(10), pp. 1837-1847. (doi: 10.7150/jca.83910) (PMID:37476187) (PMCID:PMC10355195)

Zhang, H. et al. (2023) Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma. Cancer Research, 83(9), pp. 1410-1425. (doi: 10.1158/0008-5472.CAN-22-2589) (PMID:36853169) (PMCID:PMC10152235)

May, S. et al. (2023) Absent expansion of AXIN2+ hepatocytes and altered physiology in Axin2CreERT2 mice challenges the role of pericentral hepatocytes in homeostatic liver regeneration. Journal of Hepatology, 78(5), pp. 1028-1036. (doi: 10.1016/j.jhep.2023.01.009) (PMID:36702176)

Abbosh, C. et al. (2023) Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature, 616(7957), pp. 553-562. (doi: 10.1038/s41586-023-05776-4) (PMID:37055640)

Al Bakir, M. et al. (2023) The evolution of non-small cell lung cancer metastases in TRACERx. Nature, 616, pp. 534-542. (doi: 10.1038/s41586-023-05729-x) (PMID:37046095) (PMCID:PMC10115651)

Frankell, A. M. et al. (2023) The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 616, pp. 525-533. (doi: 10.1038/s41586-023-05783-5) (PMID:37046096) (PMCID:PMC10115649)

Martínez-Ruiz, C. et al. (2023) Genomic–transcriptomic evolution in lung cancer and metastasis. Nature, 616, pp. 543-552. (doi: 10.1038/s41586-023-05706-4) (PMID:37046093) (PMCID:PMC10115639)

Ng, K. W. et al. (2023) Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature, 616, pp. 563-573. (doi: 10.1038/s41586-023-05771-9) (PMID:37046094) (PMCID:PMC10115647)

Hill, W. et al. (2023) Lung adenocarcinoma promotion by air pollutants. Nature, 616(7955), pp. 159-167. (doi: 10.1038/s41586-023-05874-3) (PMID:37020004)

Al-Sawaf, O. et al. (2023) Body composition and lung cancer-associated cachexia in TRACERx. Nature Medicine, 29(4), pp. 846-858. (doi: 10.1038/s41591-023-02232-8) (PMID:37045997) (PMCID:PMC7614477)

Karasaki, T. et al. (2023) Evolutionary characterization of lung adenocarcinoma morphology in TRACERx. Nature Medicine, 29(4), pp. 833-845. (doi: 10.1038/s41591-023-02230-w) (PMID:37045996) (PMCID:PMC7614478)

Schmidt, T. et al. (2023) eIF4A1-dependent mRNAs employ purine-rich 5’UTR sequences to activate localised eIF4A1-unwinding through eIF4A1-multimerisation to facilitate translation. Nucleic Acids Research, 51(4), pp. 1859-1879. (doi: 10.1093/nar/gkad030) (PMID:36727461) (PMCID:PMC9976904)

Román-Fernández, A. et al. (2023) Spatial regulation of the glycocalyx component podocalyxin is a switch for prometastatic function. Science Advances, 9(5), eabq1858. (doi: 10.1126/sciadv.abq1858) (PMID:36735782) (PMCID:PMC9897673)

2021

Bao, J., Närhi, K., Teodòsio, A., Hemmes, A., Linnavirta, N. M., Mäyränpää, M. I., Salmenkivi, K., Le Quesne, J. and Verschuren, E. W. (2021) SOX9 has distinct roles in the formation and progression of different non‐small cell lung cancer histotypes. Journal of Pathology, 255(1), pp. 16-29. (doi: 10.1002/path.5733) (PMID:34021911)

Marini, A. et al. (2021) The pathogenesis of mesothelioma is driven by a dysregulated translatome. Nature Communications, 12, 4920. (doi: 10.1038/s41467-021-25173-7) (PMID:34389715) (PMCID:PMC8363647)

Ghaddar, N. et al. (2021) The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer. Nature Communications, 12, 4651. (doi: 10.1038/s41467-021-24661-0) (PMID:34330898) (PMCID:PMC8324901)

Ntala, C. et al. (2021) Analysis of prostate cancer tumor microenvironment identifies reduced stromal CD4 effector T-cell infiltration in tumors with pelvic nodal metastasis. European Urology Open Science, 29, pp. 19-29. (doi: 10.1016/j.euros.2021.05.001) (PMID:34337530) (PMCID:PMC8317840)

Knight, J. R.P. et al. (2021) MNK inhibition sensitizes KRAS-mutant colorectal cancer to mTORC1 inhibition by reducing eIF4E phosphorylation and c-MYC expression. Cancer Discovery, 11(5), pp. 1228-1247. (doi: 10.1158/2159-8290.CD-20-0652) (PMID:33328217)

Sereno, M. et al. (2021) Inclusion of multiple high‐risk histopathological criteria improves the prediction of adjuvant chemotherapy efficacy in lung adenocarcinoma. Histopathology, 78(6), pp. 838-848. (doi: 10.1111/his.14301) (PMID:33155719) (PMCID:PMC8247971)

Busacca, S. et al. (2021) Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression. Scientific Reports, 11, 7434. (doi: 10.1038/s41598-021-86834-7) (PMID:33795785) (PMCID:PMC8016828)

Zhang, M. et al. (2021) Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nature Communications, 12, 1751. (doi: 10.1038/s41467-021-21798-w) (PMID:33741915) (PMCID:PMC7979861)

Phatak, V. et al. (2021) Mutant p53 promotes RCP-dependent chemoresistance coinciding with increased delivery of P-glycoprotein to the plasma membrane. Cell Death and Disease, 12(2), 207. (doi: 10.1038/s41419-021-03497-y) (PMID:33627632) (PMCID:PMC7904762)

Jensen, M. P., Le Quesne, J., Officer‐Jones, L., Teodòsio, A., Thaventhiran, J., Ficken, C., Goddard, M., Smith, C., Menon, D. and Allinson, K. S. J. (2021) Neuropathological findings in two patients with fatal COVID‐19. Neuropathology and Applied Neurobiology, 47(1), pp. 17-25. (doi: 10.1111/nan.12662) (PMID:32895961)

2020

Valtonen, S., Vuorinen, E., Kariniemi, T., Eskonen, V., Le Quesne, J., Bushell, M., Härmä, H. and Kopra, K. (2020) Nanomolar Protein-Protein Interaction monitoring with a label-free protein-probe technique. Analytical chemistry, 92(24), pp. 15781-15788. (doi: 10.1021/acs.analchem.0c02823) (PMID:33237744) (PMCID:PMC7745204)

Fercoq, F., Remion, E., Vallarino-Lhermitte, N., Alonso, J., Raveendran, L., Nixon, C., Le Quesne, J., Carlin, L. M. and Martin, C. (2020) Microfilaria-dependent thoracic pathology associated with eosinophilic and fibrotic polyps in filaria-infected rodents. Parasites and Vectors, 13, 531. (doi: 10.1186/s13071-020-04428-0) (PMID:33160409) (PMCID:PMC7648300)

Curtin, N., Bányai, K., Thaventhiran, J., Le Quesne, J., Helyes, Z. and Bai, P. (2020) Repositioning PARP inhibitors for SARS‐CoV‐2 infection(COVID‐19); a new multi‐pronged therapy for acute respiratory distress syndrome? British Journal of Pharmacology, 177(16), pp. 3635-3645. (doi: 10.1111/bph.15137) (PMID:32441764) (PMCID:PMC7280733)

AbdulJabbar, K. et al. (2020) Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nature Medicine, 26(7), pp. 1054-1062. (doi: 10.1038/s41591-020-0900-x) (PMID:32461698)

Kos, Z. et al. (2020) Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. npj Breast Cancer, 6, 17. (doi: 10.1038/s41523-020-0156-0) (PMID:32411819) (PMCID:PMC7217863)

Litchfield, K. et al. (2020) Representative sequencing: unbiased sampling of solid tumor tissue. Cell Reports, 31(5), 107550. (doi: 10.1016/j.celrep.2020.107550) (PMID:32375028)

Gonzalez‐Ericsson, P. I. et al. (2020) The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice. Journal of Pathology, 250(5), pp. 667-684. (doi: 10.1002/path.5406) (PMID:32129476)

Ghaddar, N. et al. (2020) The integrated stress response exposes a therapeutic vulnerability in KRAS driven lung cancer. European Journal of Cancer, 138, S23. (doi: 10.1016/S0959-8049(20)31126-6)

Officer, L. K., Andreou, K. E., Teodósio, A. V., He, Z. and Le Quesne, J. P. (2020) Automated co-in situ hybridization and immunofluorescence using archival tumor tissue. In: Nielsen, B. S. and Jones, J. (eds.) In Situ Hybridization Protocols. Series: Methods in molecular biology, 2148 (2148). Springer, pp. 245-256. ISBN 9781071606230 (doi: 10.1007/978-1-0716-0623-0_16)

2019

Waldron, J. A., Tack, D. C., Ritchey, L. E., Gillen, S. L., Wilczynska, A., Turro, E., Bevilacqua, P. C., Assmann, S. M., Bushell, M. and Le Quesne, J. (2019) mRNA structural elements immediately upstream of the start codon dictate dependence upon eIF4A helicase activity. Genome Biology, 20(1), 300. (doi: 10.1186/s13059-019-1901-2) (PMID:31888698) (PMCID:PMC6936103)

Le Quesne, J., Pritchard, C., Officer, L., Kamata, T., Smith, C., Sereno, M., Das, M., Baena, J. and Al Dujaily, E. (2019) Reduced protumorigenic tumor-associated macrophages with statin use in premalignant human lung adenocarcinoma. JNCI Cancer Spectrum, 4(2), pkz101. (doi: 10.1093/jncics/pkz101) (PMID:32190817) (PMCID:PMC7068793)

Wilczynska, A. et al. (2019) eIF4A2 drives repression of translation at initiation by Ccr4-Not through purine-rich motifs in the 5’UTR. Genome Biology, 20, 262. (doi: 10.1186/s13059-019-1857-2) (PMID:31791371) (PMCID:PMC6886185)

Fercoq, F., Remion, E., Frohberger, S. J., Vallarino-Lhermitte, N., Hoerauf, A., Le Quesne, J., Landmann, F., Hübner, M. P., Carlin, L. M. and Martin, C. (2019) IL-4 receptor dependent expansion of lung CD169+ macrophages in microfilaria-driven inflammation. PLoS Neglected Tropical Diseases, 13(8), e0007691. (doi: 10.1371/journal.pntd.0007691) (PMID:31469835) (PMCID:PMC6742411)

Moore, D. A. et al. (2019) In situ growth in early lung adenocarcinoma may represent precursor growth or invasive clone outgrowth—a clinically relevant distinction. Modern Pathology, 32(8), pp. 1095-1105. (doi: 10.1038/s41379-019-0257-1) (PMID:30932019)

Rosenthal, R. et al. (2019) Neoantigen-directed immune escape in lung cancer evolution. Nature, 567(7749), pp. 479-485. (doi: 10.1038/s41586-019-1032-7) (PMID:30894752) (PMCID:PMC6954100)

Rakhit, C. P., Trigg, R. M., Le Quesne, J., Kelly, M., Shaw, J. A., Pritchard, C. and Martins, L. M. (2019) Early detection of pre-malignant lesions in a KRASG12D-driven mouse lung cancer model by monitoring circulating free DNA. Disease Models and Mechanisms, 12(2), dmm036863. (doi: 10.1242/dmm.036863) (PMID:30760495) (PMCID:PMC6398498)

2018

Amelio, I. et al. (2018) p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 115(46), E10869-E10878. (doi: 10.1073/pnas.1808314115) (PMID:30381462) (PMCID:PMC6243248)

Lazarus, K. A. et al. (2018) BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous carcinoma. Nature Communications, 9, 3327. (doi: 10.1038/s41467-018-05790-5) (PMID:30127402) (PMCID:PMC6102279)

Mackay, H. L. et al. (2018) Genomic instability in mutant p53 cancer cells upon entotic engulfment. Nature Communications, 9, 3070. (doi: 10.1038/s41467-018-05368-1) (PMID:30076358) (PMCID:PMC6076230)

Kruspig, B. et al. (2018) The ERBB network facilitates KRAS-driven lung tumorigenesis. Science Translational Medicine, 10(446), eaao2565. (doi: 10.1126/scitranslmed.aao2565) (PMID:29925636) (PMCID:PMC6881183)

Arce Vargas, F. et al. (2018) Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell, 33(4), 649-663.e4. (doi: 10.1016/j.ccell.2018.02.010) (PMID:29576375) (PMCID:PMC5904288)

Waldron, J. A., Raza, F. and Le Quesne, J. (2018) eIF4A alleviates the translational repression mediated by classical secondary structures more than by G-quadruplexes. Nucleic Acids Research, 46(6), pp. 3075-3087. (doi: 10.1093/nar/gky108) (PMID:29471358) (PMCID:PMC5888628)

Kolluri, K. K. et al. (2018) Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells. eLife, 7, e30224. (doi: 10.7554/eLife.30224) (PMID:29345617) (PMCID:PMC5773178)

2017

Chernova, T. et al. (2017) Long-fiber carbon nanotubes replicate asbestos-induced mesothelioma with disruption of the tumor suppressor gene Cdkn2a ( Ink4a/Arf ). Current Biology, 27(21), 3302-3314.e6. (doi: 10.1016/j.cub.2017.09.007) (PMID:29112861) (PMCID:PMC5681354)

Jamal-Hanjani, M. et al. (2017) Tracking the evolution of non–small-cell lung cancer. New England Journal of Medicine, 376(22), pp. 2109-2121. (doi: 10.1056/NEJMoa1616288) (PMID:28445112)

Abbosh, C. et al. (2017) Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 545(7655), pp. 446-451. (doi: 10.1038/nature22364) (PMID:28445469) (PMCID:PMC5812436)

Arce Vargas, F. et al. (2017) Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity, 46(4), pp. 577-586. (doi: 10.1016/j.immuni.2017.03.013) (PMID:28410988) (PMCID:PMC5437702)

Karekla, E., Liao, W.-J., Sharp, B., Pugh, J., Reid, H., Le Quesne, J., Moore, D., Pritchard, C., MacFarlane, M. and Pringle, J. H. (2017) Ex vivo explant cultures of non–small cell lung carcinoma enable evaluation of primary tumor responses to anticancer therapy. Cancer Research, 77(8), pp. 2029-2039. (doi: 10.1158/0008-5472.CAN-16-1121) (PMID:28202521)

2014

Jamal-Hanjani, M. et al. (2014) Tracking genomic cancer evolution for precision medicine: The Lung TRACERx Study. PLoS Biology, 12(7), e1001906. (doi: 10.1371/journal.pbio.1001906) (PMID:25003521) (PMCID:PMC4086714)

Turnock-Jones, J. J. and Le Quesne, J. P.C. (2014) MicroRNA in situ hybridization in tissue microarrays. In: Nielsen, B. S. (ed.) In Situ Hybridization Protocols. Series: Methods in molecular biology, 1211 (1211). Humana Press, pp. 85-93. ISBN 9781493914586 (doi: 10.1007/978-1-4939-1459-3_8)

Articles

Frankell, A. M. et al. (2024) Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 631(8022), E15. (doi: 10.1038/s41586-024-07738-w) (PMID:38965439)

Quiros, A. C. et al. (2024) Mapping the landscape of histomorphological cancer phenotypes using self-supervised learning on unannotated pathology slides. Nature Communications, 15, 4596. (doi: 10.1038/s41467-024-48666-7) (PMID:38862472)

Farahmand, P. et al. (2023) Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma. Frontiers in Toxicology, 5, 1200650. (doi: 10.3389/ftox.2023.1200650) (PMID:37441092) (PMCID:PMC10333928)

Hatthakarnkul, P. et al. (2023) Protein expression of S100A2 reveals it association with patient prognosis and immune infiltration profile in colorectal cancer. Journal of Cancer, 14(10), pp. 1837-1847. (doi: 10.7150/jca.83910) (PMID:37476187) (PMCID:PMC10355195)

Zhang, H. et al. (2023) Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma. Cancer Research, 83(9), pp. 1410-1425. (doi: 10.1158/0008-5472.CAN-22-2589) (PMID:36853169) (PMCID:PMC10152235)

May, S. et al. (2023) Absent expansion of AXIN2+ hepatocytes and altered physiology in Axin2CreERT2 mice challenges the role of pericentral hepatocytes in homeostatic liver regeneration. Journal of Hepatology, 78(5), pp. 1028-1036. (doi: 10.1016/j.jhep.2023.01.009) (PMID:36702176)

Abbosh, C. et al. (2023) Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature, 616(7957), pp. 553-562. (doi: 10.1038/s41586-023-05776-4) (PMID:37055640)

Al Bakir, M. et al. (2023) The evolution of non-small cell lung cancer metastases in TRACERx. Nature, 616, pp. 534-542. (doi: 10.1038/s41586-023-05729-x) (PMID:37046095) (PMCID:PMC10115651)

Frankell, A. M. et al. (2023) The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 616, pp. 525-533. (doi: 10.1038/s41586-023-05783-5) (PMID:37046096) (PMCID:PMC10115649)

Martínez-Ruiz, C. et al. (2023) Genomic–transcriptomic evolution in lung cancer and metastasis. Nature, 616, pp. 543-552. (doi: 10.1038/s41586-023-05706-4) (PMID:37046093) (PMCID:PMC10115639)

Ng, K. W. et al. (2023) Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature, 616, pp. 563-573. (doi: 10.1038/s41586-023-05771-9) (PMID:37046094) (PMCID:PMC10115647)

Hill, W. et al. (2023) Lung adenocarcinoma promotion by air pollutants. Nature, 616(7955), pp. 159-167. (doi: 10.1038/s41586-023-05874-3) (PMID:37020004)

Al-Sawaf, O. et al. (2023) Body composition and lung cancer-associated cachexia in TRACERx. Nature Medicine, 29(4), pp. 846-858. (doi: 10.1038/s41591-023-02232-8) (PMID:37045997) (PMCID:PMC7614477)

Karasaki, T. et al. (2023) Evolutionary characterization of lung adenocarcinoma morphology in TRACERx. Nature Medicine, 29(4), pp. 833-845. (doi: 10.1038/s41591-023-02230-w) (PMID:37045996) (PMCID:PMC7614478)

Schmidt, T. et al. (2023) eIF4A1-dependent mRNAs employ purine-rich 5’UTR sequences to activate localised eIF4A1-unwinding through eIF4A1-multimerisation to facilitate translation. Nucleic Acids Research, 51(4), pp. 1859-1879. (doi: 10.1093/nar/gkad030) (PMID:36727461) (PMCID:PMC9976904)

Román-Fernández, A. et al. (2023) Spatial regulation of the glycocalyx component podocalyxin is a switch for prometastatic function. Science Advances, 9(5), eabq1858. (doi: 10.1126/sciadv.abq1858) (PMID:36735782) (PMCID:PMC9897673)

Bao, J., Närhi, K., Teodòsio, A., Hemmes, A., Linnavirta, N. M., Mäyränpää, M. I., Salmenkivi, K., Le Quesne, J. and Verschuren, E. W. (2021) SOX9 has distinct roles in the formation and progression of different non‐small cell lung cancer histotypes. Journal of Pathology, 255(1), pp. 16-29. (doi: 10.1002/path.5733) (PMID:34021911)

Marini, A. et al. (2021) The pathogenesis of mesothelioma is driven by a dysregulated translatome. Nature Communications, 12, 4920. (doi: 10.1038/s41467-021-25173-7) (PMID:34389715) (PMCID:PMC8363647)

Ghaddar, N. et al. (2021) The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer. Nature Communications, 12, 4651. (doi: 10.1038/s41467-021-24661-0) (PMID:34330898) (PMCID:PMC8324901)

Ntala, C. et al. (2021) Analysis of prostate cancer tumor microenvironment identifies reduced stromal CD4 effector T-cell infiltration in tumors with pelvic nodal metastasis. European Urology Open Science, 29, pp. 19-29. (doi: 10.1016/j.euros.2021.05.001) (PMID:34337530) (PMCID:PMC8317840)

Knight, J. R.P. et al. (2021) MNK inhibition sensitizes KRAS-mutant colorectal cancer to mTORC1 inhibition by reducing eIF4E phosphorylation and c-MYC expression. Cancer Discovery, 11(5), pp. 1228-1247. (doi: 10.1158/2159-8290.CD-20-0652) (PMID:33328217)

Sereno, M. et al. (2021) Inclusion of multiple high‐risk histopathological criteria improves the prediction of adjuvant chemotherapy efficacy in lung adenocarcinoma. Histopathology, 78(6), pp. 838-848. (doi: 10.1111/his.14301) (PMID:33155719) (PMCID:PMC8247971)

Busacca, S. et al. (2021) Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression. Scientific Reports, 11, 7434. (doi: 10.1038/s41598-021-86834-7) (PMID:33795785) (PMCID:PMC8016828)

Zhang, M. et al. (2021) Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nature Communications, 12, 1751. (doi: 10.1038/s41467-021-21798-w) (PMID:33741915) (PMCID:PMC7979861)

Phatak, V. et al. (2021) Mutant p53 promotes RCP-dependent chemoresistance coinciding with increased delivery of P-glycoprotein to the plasma membrane. Cell Death and Disease, 12(2), 207. (doi: 10.1038/s41419-021-03497-y) (PMID:33627632) (PMCID:PMC7904762)

Jensen, M. P., Le Quesne, J., Officer‐Jones, L., Teodòsio, A., Thaventhiran, J., Ficken, C., Goddard, M., Smith, C., Menon, D. and Allinson, K. S. J. (2021) Neuropathological findings in two patients with fatal COVID‐19. Neuropathology and Applied Neurobiology, 47(1), pp. 17-25. (doi: 10.1111/nan.12662) (PMID:32895961)

Valtonen, S., Vuorinen, E., Kariniemi, T., Eskonen, V., Le Quesne, J., Bushell, M., Härmä, H. and Kopra, K. (2020) Nanomolar Protein-Protein Interaction monitoring with a label-free protein-probe technique. Analytical chemistry, 92(24), pp. 15781-15788. (doi: 10.1021/acs.analchem.0c02823) (PMID:33237744) (PMCID:PMC7745204)

Fercoq, F., Remion, E., Vallarino-Lhermitte, N., Alonso, J., Raveendran, L., Nixon, C., Le Quesne, J., Carlin, L. M. and Martin, C. (2020) Microfilaria-dependent thoracic pathology associated with eosinophilic and fibrotic polyps in filaria-infected rodents. Parasites and Vectors, 13, 531. (doi: 10.1186/s13071-020-04428-0) (PMID:33160409) (PMCID:PMC7648300)

Curtin, N., Bányai, K., Thaventhiran, J., Le Quesne, J., Helyes, Z. and Bai, P. (2020) Repositioning PARP inhibitors for SARS‐CoV‐2 infection(COVID‐19); a new multi‐pronged therapy for acute respiratory distress syndrome? British Journal of Pharmacology, 177(16), pp. 3635-3645. (doi: 10.1111/bph.15137) (PMID:32441764) (PMCID:PMC7280733)

AbdulJabbar, K. et al. (2020) Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nature Medicine, 26(7), pp. 1054-1062. (doi: 10.1038/s41591-020-0900-x) (PMID:32461698)

Kos, Z. et al. (2020) Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. npj Breast Cancer, 6, 17. (doi: 10.1038/s41523-020-0156-0) (PMID:32411819) (PMCID:PMC7217863)

Litchfield, K. et al. (2020) Representative sequencing: unbiased sampling of solid tumor tissue. Cell Reports, 31(5), 107550. (doi: 10.1016/j.celrep.2020.107550) (PMID:32375028)

Gonzalez‐Ericsson, P. I. et al. (2020) The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice. Journal of Pathology, 250(5), pp. 667-684. (doi: 10.1002/path.5406) (PMID:32129476)

Ghaddar, N. et al. (2020) The integrated stress response exposes a therapeutic vulnerability in KRAS driven lung cancer. European Journal of Cancer, 138, S23. (doi: 10.1016/S0959-8049(20)31126-6)

Waldron, J. A., Tack, D. C., Ritchey, L. E., Gillen, S. L., Wilczynska, A., Turro, E., Bevilacqua, P. C., Assmann, S. M., Bushell, M. and Le Quesne, J. (2019) mRNA structural elements immediately upstream of the start codon dictate dependence upon eIF4A helicase activity. Genome Biology, 20(1), 300. (doi: 10.1186/s13059-019-1901-2) (PMID:31888698) (PMCID:PMC6936103)

Le Quesne, J., Pritchard, C., Officer, L., Kamata, T., Smith, C., Sereno, M., Das, M., Baena, J. and Al Dujaily, E. (2019) Reduced protumorigenic tumor-associated macrophages with statin use in premalignant human lung adenocarcinoma. JNCI Cancer Spectrum, 4(2), pkz101. (doi: 10.1093/jncics/pkz101) (PMID:32190817) (PMCID:PMC7068793)

Wilczynska, A. et al. (2019) eIF4A2 drives repression of translation at initiation by Ccr4-Not through purine-rich motifs in the 5’UTR. Genome Biology, 20, 262. (doi: 10.1186/s13059-019-1857-2) (PMID:31791371) (PMCID:PMC6886185)

Fercoq, F., Remion, E., Frohberger, S. J., Vallarino-Lhermitte, N., Hoerauf, A., Le Quesne, J., Landmann, F., Hübner, M. P., Carlin, L. M. and Martin, C. (2019) IL-4 receptor dependent expansion of lung CD169+ macrophages in microfilaria-driven inflammation. PLoS Neglected Tropical Diseases, 13(8), e0007691. (doi: 10.1371/journal.pntd.0007691) (PMID:31469835) (PMCID:PMC6742411)

Moore, D. A. et al. (2019) In situ growth in early lung adenocarcinoma may represent precursor growth or invasive clone outgrowth—a clinically relevant distinction. Modern Pathology, 32(8), pp. 1095-1105. (doi: 10.1038/s41379-019-0257-1) (PMID:30932019)

Rosenthal, R. et al. (2019) Neoantigen-directed immune escape in lung cancer evolution. Nature, 567(7749), pp. 479-485. (doi: 10.1038/s41586-019-1032-7) (PMID:30894752) (PMCID:PMC6954100)

Rakhit, C. P., Trigg, R. M., Le Quesne, J., Kelly, M., Shaw, J. A., Pritchard, C. and Martins, L. M. (2019) Early detection of pre-malignant lesions in a KRASG12D-driven mouse lung cancer model by monitoring circulating free DNA. Disease Models and Mechanisms, 12(2), dmm036863. (doi: 10.1242/dmm.036863) (PMID:30760495) (PMCID:PMC6398498)

Amelio, I. et al. (2018) p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 115(46), E10869-E10878. (doi: 10.1073/pnas.1808314115) (PMID:30381462) (PMCID:PMC6243248)

Lazarus, K. A. et al. (2018) BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous carcinoma. Nature Communications, 9, 3327. (doi: 10.1038/s41467-018-05790-5) (PMID:30127402) (PMCID:PMC6102279)

Mackay, H. L. et al. (2018) Genomic instability in mutant p53 cancer cells upon entotic engulfment. Nature Communications, 9, 3070. (doi: 10.1038/s41467-018-05368-1) (PMID:30076358) (PMCID:PMC6076230)

Kruspig, B. et al. (2018) The ERBB network facilitates KRAS-driven lung tumorigenesis. Science Translational Medicine, 10(446), eaao2565. (doi: 10.1126/scitranslmed.aao2565) (PMID:29925636) (PMCID:PMC6881183)

Arce Vargas, F. et al. (2018) Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell, 33(4), 649-663.e4. (doi: 10.1016/j.ccell.2018.02.010) (PMID:29576375) (PMCID:PMC5904288)

Waldron, J. A., Raza, F. and Le Quesne, J. (2018) eIF4A alleviates the translational repression mediated by classical secondary structures more than by G-quadruplexes. Nucleic Acids Research, 46(6), pp. 3075-3087. (doi: 10.1093/nar/gky108) (PMID:29471358) (PMCID:PMC5888628)

Kolluri, K. K. et al. (2018) Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells. eLife, 7, e30224. (doi: 10.7554/eLife.30224) (PMID:29345617) (PMCID:PMC5773178)

Chernova, T. et al. (2017) Long-fiber carbon nanotubes replicate asbestos-induced mesothelioma with disruption of the tumor suppressor gene Cdkn2a ( Ink4a/Arf ). Current Biology, 27(21), 3302-3314.e6. (doi: 10.1016/j.cub.2017.09.007) (PMID:29112861) (PMCID:PMC5681354)

Jamal-Hanjani, M. et al. (2017) Tracking the evolution of non–small-cell lung cancer. New England Journal of Medicine, 376(22), pp. 2109-2121. (doi: 10.1056/NEJMoa1616288) (PMID:28445112)

Abbosh, C. et al. (2017) Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 545(7655), pp. 446-451. (doi: 10.1038/nature22364) (PMID:28445469) (PMCID:PMC5812436)

Arce Vargas, F. et al. (2017) Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity, 46(4), pp. 577-586. (doi: 10.1016/j.immuni.2017.03.013) (PMID:28410988) (PMCID:PMC5437702)

Karekla, E., Liao, W.-J., Sharp, B., Pugh, J., Reid, H., Le Quesne, J., Moore, D., Pritchard, C., MacFarlane, M. and Pringle, J. H. (2017) Ex vivo explant cultures of non–small cell lung carcinoma enable evaluation of primary tumor responses to anticancer therapy. Cancer Research, 77(8), pp. 2029-2039. (doi: 10.1158/0008-5472.CAN-16-1121) (PMID:28202521)

Jamal-Hanjani, M. et al. (2014) Tracking genomic cancer evolution for precision medicine: The Lung TRACERx Study. PLoS Biology, 12(7), e1001906. (doi: 10.1371/journal.pbio.1001906) (PMID:25003521) (PMCID:PMC4086714)

Book Sections

Officer, L. K., Andreou, K. E., Teodósio, A. V., He, Z. and Le Quesne, J. P. (2020) Automated co-in situ hybridization and immunofluorescence using archival tumor tissue. In: Nielsen, B. S. and Jones, J. (eds.) In Situ Hybridization Protocols. Series: Methods in molecular biology, 2148 (2148). Springer, pp. 245-256. ISBN 9781071606230 (doi: 10.1007/978-1-0716-0623-0_16)

Turnock-Jones, J. J. and Le Quesne, J. P.C. (2014) MicroRNA in situ hybridization in tissue microarrays. In: Nielsen, B. S. (ed.) In Situ Hybridization Protocols. Series: Methods in molecular biology, 1211 (1211). Humana Press, pp. 85-93. ISBN 9781493914586 (doi: 10.1007/978-1-4939-1459-3_8)